Loading
Inherited conditions (MEN1, VHL, NF1, tuberous sclerosis) that cause neuroendocrine tumours, often multiple and at a young age, so families need genetic testing and surveillance.
MEN1 (menin loss) causes parathyroid, pituitary and pancreatic NETs; MEN1 is also the most commonly mutated gene in sporadic pancreatic NETs (~40%), with DAXX/ATRX and mTOR-pathway genes. Germline testing is recommended for pancreatic NETs, paragangliomas (SDHx) and young-onset disease. Belzutifan is approved for VHL-associated pancreatic NETs.
In plain words · A scaffold protein that certain leukaemias need to keep their genes switched on; the first drug against it was approved in 2024.
Showing the target this term concerns: Menin.
Shares HIF-2α, Belzutifan, Hereditary cancer syndromes, Neuroendocrine tumours.
Shares Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4).
Shares Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Hereditary cancer syndromes, Germline (hereditary) testing.
Shares Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Hereditary cancer syndromes, Germline (hereditary) testing.
Shares Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Hereditary cancer syndromes, Germline (hereditary) testing.
Shares Multiple endocrine neoplasia type 1 (MEN1), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Multiple endocrine neoplasia type 1 (MEN1), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Hereditary cancer syndromes, Inherited risk is mostly unidentified, Germline (hereditary) testing.